Regularly methylated novel pro‐apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder

Frank Christoph(Charité - Universitätsmedizin Berlin), Mark Schrader(Arbeitsgemeinschaft Urologische Onkologie), Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin), Kurt Miller(Charité - Universitätsmedizin Berlin), Steffen Weikert(St. Hedwig-Krankenhaus), Martin Schostak(Aturo), Hans Krause(Charité - Universitätsmedizin Berlin)

International Journal of Cancer

April 26, 2006

10.1002/ijc.21971

Cited by 55

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

|New England Journal of Medicine|2014|3k

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

|The Lancet Oncology|2015|1.4k

The Epidemiology of Renal Cell Carcinoma

|European Urology|2011|1k

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

|European Urology|2016|414

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

|The Lancet Oncology|2016|218